Table of Content

Chapter 1 Introduction
Introduction
Interleukin-2 an Important Driver for T Cell Homeostasis
Analyst’s Credentials
Related BCC Research Reports
Chapter 2 A Balancing Act
Targeted Effects
Off-Target Effects
Chapter 3 Approved IL-2 Therapies
IL-2 Antagonist Immunosuppressant
Simulet (Basilximab) Novartis
Zenapax (Daclizumab) Roche
Zinbryta (Daclizumab) AbbVie/Biogen
Leukotac (Iolimomab) ElsaLys Biotech
IL-2 Agonist Cancer Immunotherapy
Proleukin (Aldesleukin) Novartis/Chiron
Chapter 4 Future Opportunities
New Strategies to Harness IL-2’s Potential
IL-2 Monoclonal Antibodies
IL-2 Antibody Drug Conjugates
IL-2 Antibody?Cytokine Fusion Proteins
IL-2 Mutant Superkines
IL-2 Therapeutic Protein Inhibitor
IL-2 Immunotoxins
IL-2 Radioimmunoconjugates
Long-Acting Recombinant IL-2
IL-2 Based Vaccines
Chapter 5 IL-2 Watch for These Drugs
Chapter 6 References



List of Figures


Figure 1 : IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types
Figure 2 : Three Different Types of IL-2 Receptors
Figure 3 : Balancing Efficacy and Safety
Figure 4 : Drugs Targeting IL-2
Figure 5 : Computer Model of Neoleukin-2/15 Structure

 

List of Tables


Table 1 : Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells
Table 2 : Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets
Table 3 : IL-2 Agents to Watch